2,347 Shares in Cencora, Inc. $COR Purchased by Rexford Capital Inc.

Rexford Capital Inc. acquired a new stake in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 2,347 shares of the company’s stock, valued at approximately $704,000.

Other hedge funds also recently made changes to their positions in the company. Atlantic Edge Private Wealth Management LLC lifted its stake in Cencora by 70.0% during the second quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the last quarter. Vermillion & White Wealth Management Group LLC boosted its holdings in shares of Cencora by 69.4% in the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 105 shares of the company’s stock valued at $31,000 after buying an additional 43 shares during the period. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Cencora during the 2nd quarter valued at about $52,000. Hantz Financial Services Inc. raised its stake in Cencora by 712.0% during the second quarter. Hantz Financial Services Inc. now owns 203 shares of the company’s stock worth $61,000 after acquiring an additional 178 shares during the period. Finally, Caitong International Asset Management Co. Ltd bought a new position in Cencora in the second quarter worth about $61,000. Institutional investors and hedge funds own 97.52% of the company’s stock.

Insiders Place Their Bets

In other Cencora news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,096 shares of the firm’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $366.64, for a total transaction of $1,868,397.44. Following the completion of the transaction, the chief executive officer owned 65,746 shares of the company’s stock, valued at approximately $24,105,113.44. The trade was a 7.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 46,640 shares of company stock valued at $14,099,338 in the last quarter. Insiders own 10.80% of the company’s stock.

Cencora Stock Up 0.4%

COR opened at $345.86 on Friday. The company has a debt-to-equity ratio of 4.32, a quick ratio of 0.55 and a current ratio of 0.90. The company has a market capitalization of $67.09 billion, a PE ratio of 43.50, a P/E/G ratio of 1.64 and a beta of 0.63. The stock’s fifty day moving average is $343.29 and its 200-day moving average is $311.33. Cencora, Inc. has a one year low of $223.92 and a one year high of $377.54.

Cencora (NYSE:COR) last released its earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.79 by $0.05. Cencora had a return on equity of 227.15% and a net margin of 0.48%.The firm had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same period in the previous year, the company earned $3.34 earnings per share. Cencora’s revenue was up 5.9% compared to the same quarter last year. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, equities analysts predict that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were issued a $0.60 dividend. This is an increase from Cencora’s previous quarterly dividend of $0.55. This represents a $2.40 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend was Friday, November 14th. Cencora’s dividend payout ratio is currently 30.19%.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on COR. Evercore ISI set a $400.00 price target on Cencora and gave the stock an “outperform” rating in a report on Thursday, November 6th. Weiss Ratings reissued a “hold (c+)” rating on shares of Cencora in a report on Monday, December 8th. Barclays started coverage on shares of Cencora in a report on Monday, December 8th. They issued an “overweight” rating and a $400.00 price objective on the stock. Robert W. Baird upped their target price on shares of Cencora from $355.00 to $395.00 and gave the stock an “outperform” rating in a research report on Thursday, November 6th. Finally, UBS Group raised their price target on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research note on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $373.50.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.